BTIG lowered the firm’s price target on Beyond Air to $10 from $13 and keeps a Buy rating on the shares. Beyond Air’s Q2 revenue missed consensus estimates, and the number of hospitals using LungFit PH has more than doubled since the August earnings call, though it is unclear how many centers are using the technology, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XAIR:
- Beyond Air reports Q2 EPS (51c), consensus (47c)
- Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
- XAIR Upcoming Earnings Report: What to Expect?
- Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
- Beyond Cancer presents first-in-human clinical data for UNO therapy
